Logo Established for the “Japan Creator Support Fund” to Support the Global Success of Japan’s Next-Generation Creators and Artists
30.6.2025 09:00:00 EEST | Business Wire | Press release
The Japan Arts Council (President: Mariko Hasegawa), with funding from the Agency for Cultural Affairs, has established the Japan Creator Support Fund to support projects nurturing Japan’s diverse creators and artists, and to support cultural facilities’ function enhancement. We are pleased to announce that the logo for the Fund has been established and that the English-language global website, which is promoting this project overseas, has been officially launched on Monday, June 30, 2025. A promotional video for international audiences is also now available on the website.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627404244/en/
From the top left are the individual logos for the following support programs: the Creator & Artist Development Support Program [FOR CREATORS], the Support Program for Cultural Facilities Function Enhancement [FOR CULTURAL FACILITIES], the Creator Support Program (Program Development & Implementation) [FOR CREATOR DEVELOPMENT], and the Japan Creator Support Fund for Entertainment, International Outreach Program (Long-Term Projects) funded by METI [FOR ENTERTAINMENT].
About the Japan Creator Support Fund
The Japan Creator Support Fund was established within the Japan Arts Council through the supplementary budget for FY2023 by the Agency for Cultural Affairs to support initiatives for Japan-based creators and artists, and to support cultural facilities’ function enhancement. Leveraging this Fund, “Support Programs for Creator Development & Cultural Facilities Function Enhancement” has been implemented since FY2024, where 42 projects were selected, supporting a wide range of creative genres, including manga, animation, games, performing arts, contemporary art, and traditional performing arts. It aims to foster the global success of over 600 emerging Japanese creators and artists. Additionally, the “Creator Support Program (Program Development & Implementation)” was newly established through the FY2024 supplementary budget. Furthermore, we will promote the “Japan Creator Support Fund for Entertainment, International Outreach Program (Long-Term Projects)” using subsidies allocated under the FY2024 supplementary budget by the Ministry of Economy, Trade and Industry (METI). (For details on each initiative under the Fund, please refer to the attached appendix.)
Logo Established -- Inspired by the “Plane”
A new logo has been established using the motif of a “plane.” In geometry, a plane is a flat surface that extends infinitely. The design concept envisions Japanese creators, artists, and cultural arts boldly crossing borders and venturing out into the world. The plane evokes a sense of limitless expansion in all directions and represents the spread of new creativity originating in Japan.
In addition to the main logo for the Fund as a whole, individual logos were also created for the Fund’s four support programs:
- The Creator & Artist Development Support Program [FOR CREATORS]
- The Support Program for Cultural Facilities Function Enhancement [FOR CULTURAL FACILITIES]
- The Creator Support Program (Program Development & Implementation) [FOR CREATOR DEVELOPMENT]
- The Japan Creator Support Fund for Entertainment, International Outreach Program (Long-Term Projects) funded by METI [FOR ENTERTAINMENT]
Global Website Launched
The website provides an overview of the Fund, including the four support programs offered and the projects selected under each category. Each project page features links to each project’s dedicated website and social media accounts, as well as information on participating creators and advisors. A promotional video about the fund is also available on the website. In addition, the site will be updated as needed with information on the progress of each project. It will also share details on upcoming exhibitions, performances, and other events held not only in Japan but internationally as well. The website is available in both English and Japanese.
Launch Date: Monday, June 30, 2025, 15:00.
URL: https://creator.ntj.jac.go.jp/en/
Mid-Term Report Meeting for the “Support Programs for Creator Development & Cultural Facilities Function Enhancement”
On Thursday, June 5, 2025, the Japan Arts Council held a mid-term report meeting for the “Support Programs for Creator Development & Cultural Facilities Function Enhancement.” Representatives from eight of the 42 selected projects presented activity reports, followed by a roundtable discussion featuring seven up-and-coming Japanese creators active across various genres. The event concluded with a networking session to encourage future collaboration.
Date & Time: Thursday, June 5, 2025, 3:00 pm - 6:25 pm
Venue: 3rd Floor Auditorium, Ministry of Education, Culture, Sports, Science and Technology (MEXT)
View source version on businesswire.com: https://www.businesswire.com/news/home/20250627404244/en/
Contacts
For press inquiries regarding the Fund:
Japan Creator Support Fund Secretariat, Japan Arts Council
TEL: +81-50-1754-5909
E-mail: kiban-kikin@ntj.jac.go.jp
For press inquiries regarding logo and website:
Japan Creator Support Fund PR Office
Contact: Tsuji, Hirooka
TEL: +81-3-6260-4855
E-mail: bunka-creator-pr@kyodo-pr.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom